Nisa Investment Advisors LLC Acquires 12,767 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Nisa Investment Advisors LLC grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1,001.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 14,042 shares of the company's stock after acquiring an additional 12,767 shares during the period. Nisa Investment Advisors LLC's holdings in Neurocrine Biosciences were worth $1,553,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in NBIX. Proficio Capital Partners LLC purchased a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $4,714,000. HighTower Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 10.6% during the 4th quarter. HighTower Advisors LLC now owns 10,600 shares of the company's stock worth $1,447,000 after acquiring an additional 1,013 shares during the period. Sequoia Financial Advisors LLC purchased a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $243,000. EverSource Wealth Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 107.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock worth $64,000 after acquiring an additional 241 shares during the period. Finally, Avantax Advisory Services Inc. grew its holdings in shares of Neurocrine Biosciences by 11.4% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company's stock worth $395,000 after acquiring an additional 297 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on NBIX. Piper Sandler reiterated an "overweight" rating and set a $154.00 target price (down previously from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Guggenheim boosted their price target on Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC boosted their price target on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. HC Wainwright dropped their price target on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Finally, Canaccord Genuity Group boosted their price target on Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $163.91.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 457 shares of the firm's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the transaction, the insider directly owned 4,730 shares in the company, valued at $638,550. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kevin Charles Gorman sold 9,613 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the transaction, the director owned 514,596 shares in the company, valued at $61,947,066.48. The trade was a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 120,251 shares of company stock worth $14,978,602. 4.80% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Stock Up 1.7%

NBIX stock traded up $2.24 during trading on Wednesday, reaching $133.48. The company's stock had a trading volume of 905,536 shares, compared to its average volume of 1,146,449. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $157.98. The company has a market capitalization of $13.21 billion, a P/E ratio of 45.25, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. The company's fifty day moving average is $125.18 and its 200-day moving average is $121.53.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The firm had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The company's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.20 EPS. Analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.